Results 81 to 90 of about 16,336,802 (316)

An Exploratory Analysis of the Association Between Catechol-O-Methyltransferase and Response to a Randomized Open-Label Placebo Treatment for Cancer-Related Fatigue

Frontiers in Psychiatry, 2021
Previous studies have identified catechol-O-methyltransferase (COMT), as a key enzyme influencing sympathetic function. Although the COMT SNP rs4680 and rs4818, are well-studied, little is known about their influence on cancer-related fatigue (CrF) and ...
Teri W. Hoenemeyer, N. Baidwan, Kathryn T. Hall, T. Kaptchuk, K. Fontaine, T. Mehta   +5 more
semanticscholar   +1 more source

Open-label placebos for menopausal hot flushes: a randomized controlled trial [PDF]

Scientific Reports, 2020
AbstractThis study investigated the efficacy of an open-label placebo (OLP) treatment for menopausal hot flushes. Women with at least five moderate or severe hot flushes per day were allocated to receive four weeks of OLP for twice a day or no-treatment. Intention-to-treat analyses included n = 100 women.
Pan, Yiqi, Meister, Ramona, Löwe, Bernd, Kaptchuk, Ted J., Buhling, Kai J., Nestoriuc, Yvonne   +5 more
openaire   +2 more sources

Effect of open-label placebo on exercise performance in female cyclists.

, 2021
O efeito placebo é uma resposta psicobiológica gerada a partir da crença de que uma intervenção positiva foi recebida. A ideia de que a expectativa no tratamento e o protocolo enganoso são necessários para a geração do efeito placebo tem sido contestados
Saito, Tiemi Raquel de Moraes
core   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Open-label placebo using the example of kinesio-tape - A possible ethical alternative in physiotherapy

, 2021
Hintergrund: Die Anwendung von Placebo sorgt seit jeher für ein ethisches Dilemma. Erste Forschungsergebnisse zu Open-label Placebo deuten jedoch darauf hin, dass Placebo sogar dann wirksam sein könnte, wenn Patient*innen ausdrücklich darüber aufgeklärt ...
Österreicher, Ivo
core   +2 more sources

Randomized, Placebo-Controlled, Double-Blind and Open-Label Studies in the Treatment and Prevention of Acute Diarrhea With Enterococcus faecium SF68

Frontiers in Medicine, 2020
Enterococcus faecium SF68® (SF68) is a licensed pharmaceutical for treatment and prevention of diarrhea in Austria, Italy and Switzerland. However, as for other probiotics, evidence for its efficacy is based on small to medium-sized studies.
Thomas Greuter, Thomas Greuter, Martin C. Michel, Daniela Thomann, Harald Weigmann, Stephan R. Vavricka, Stephan R. Vavricka   +6 more
doaj   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]

BMC Psychiatry, 2005
Background Although serotonin reuptake inhibitors are effective in the treatment of OCD, many patients fail to respond to these agents. Growing evidence from open-label and placebo-controlled trials suggests a role for augmentation of SRIs with atypical ...
van Ameringen Michael, Muller Jacqueline E, Seedat Soraya, Vythilingum Bavanisha, Carey Paul D, Stein Dan J   +5 more
doaj   +1 more source

Even when you know it is a placebo, you experience less sadness: First evidence from an experimental open-label placebo investigation (Open Data and Open Materials)

, 2022
Open Data and Open Materials of: Even when you know it is a placebo, you experience less sadness: First evidence from an experimental open-label placebo investigation. Journal of Affective Disorders.
Hermann, Christiane, Göhler, Annelie C., Winkler, Alexander, Hahn, Alannah   +3 more
core   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source